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Statement of translational relevance (120-150 words) ʹͷ 
Treatment for the premalignant condition Vulval Intraepithelial Neoplasia (VIN) is ʹ͸ 
primarily surgical, however topical therapy offers many advantages. In a recent ʹ͹ 
clinical trial, we evaluated treatment of VIN using the antiviral nucleoside analogue ʹͺ 
cidofovir, and TLR- agonist imiquimod. Both agents were effective in approximately ʹͻ 
half the patients treated. We now report a strong association between methylation of ͵Ͳ 
HPV DNA in pre-treatment biopsies and response to treatment.  High levels of ͵ͳ 
methylation were associated with response to cidofovir and low levels with response ͵ʹ 
to imiquimod. This suggests that the two treatments may be effective in two ͵͵ 
biologically distinct patient groups. These findings have two major implications. ͵Ͷ 
Firstly, that a high proportion of patients could be successfully treated using a non-͵ͷ 
surgical approach if, after further prospective validation, HPV DNA methylation was ͵͸ 
used as a predictive biomarker. Secondly, that similar success rates might be ͵͹ 
achievable using cidofovir and imiquimod in combination.  ͵ͺ 
 ͵ͻ 
 ͶͲ 
 Ͷͳ 
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Abstract Ͷ͵ 
Purpose ͶͶ 
Response rates to treatment of vulval intraepithelial neoplasia (VIN) with imiquimod Ͷͷ 
and cidofovir are approximately 57% and 61% respectively. Treatment is associated Ͷ͸ 
with significant side effects and, if ineffective, risk of malignant progression.  Ͷ͹ 
Treatment response is not predicted by clinical factors. Identification of a biomarker Ͷͺ 
that could predict response is an attractive prospect. This work investigated HPV Ͷͻ 
DNA methylation as a potential predictive biomarker in this setting. ͷͲ 
Experimental design ͷͳ 
DNA from 167 cases of VIN 3 from the RT3 VIN clinical trial was assessed. HPV ͷʹ 
positive cases were identified using: Greiner PapilloCheck and HPV 16 type-specific ͷ͵ 
PCR. HPV DNA methylation status was assessed in three viral regions: E2, L1/L2, ͷͶ 
and the promoter, using pyrosequencing.  ͷͷ 
Results ͷ͸ 
Methylation of the HPV E2 region was associated with response to treatment. For ͷ͹ 
cidofovir (n=30), median E2 methylation was significantly higher in patients who ͷͺ 
responded (p = <0.0001); E2 methylation >4% predicted response with 88.2% ͷͻ 
sensitivity and 84.6% specificity. For imiquimod (n=33), median E2 methylation was ͸Ͳ 
lower in patients who responded to treatment (p = 0.03 (not significant after ͸ͳ 
Bonferroni correction)); E2 methylation <4% predicted response with 70.6% ͸ʹ 
sensitivity and 62.5% specificity. ͸͵ 
Conclusions ͸Ͷ 
These data indicate that cidofovir and imiquimod may be effective in two biologically ͸ͷ 
defined groups. HPV E2 DNA methylation demonstrated potential as a predictive ͸͸ 
biomarker for the treatment of VIN with cidofovir and may warrant investigation in a ͸͹ 
biomarker-guided clinical trial.  ͸ͺ 
 ͸ͻ 
 ͹Ͳ 
 ͹ͳ 
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Introduction ͹ʹ 
Vulval intraepithelial neoplasia (VIN) is a chronic condition of vulval skin that is ͹͵ 
diagnosed histologically by the identification of cellular changes associated with a ͹Ͷ 
pre-malignant state. VIN is commonly caused by Human Papillomavirus (HPV), ͹ͷ 
which is present in around 85% of cases (1). VIN can be very distressing for patients ͹͸ 
and often takes a long time to diagnose. If untreated, VIN may progress to vulval ͹͹ 
cancer.  ͹ͺ 
Currently, most cases of VIN are managed surgically. The aims of management are ͹ͻ 
reduction in risk of malignant progression, symptom alleviation (2) and confirmation ͺͲ 
of the absence of stromal invasion (as occult malignancies are reported in up to 20.5% ͺͳ 
of cases (3)). The extent of surgery required depends on the extent of disease and can ͺʹ 
therefore range from local excision, to partial or complete vulvectomy with ͺ͵ 
reconstructive surgery. Due to the location of disease, rates of wound infection and ͺͶ 
breakdown are high. These procedures affect both the anatomy and function of the ͺͷ 
vulva and may be associated with significant psychosocial distress (4). Despite the ͺ͸ 
excision of disease, recurrence rates are unacceptably high. A systematic review ͺ͹ 
performed in 2005 revealed recurrence rates of 19% following complete vulvectomy, ͺͺ 
18% following partial vulvectomy and 22% following local excision (5). This results ͺͻ 
in repeated surgical procedures, and causes significant distress to patients (6). A ͻͲ 
growing number of younger women are presenting with VIN, and surgical excision is ͻͳ 
an increasingly unattractive option for both patients and clinicians (7).  ͻʹ 
Management options that preserve vulval tissue are urgently needed. Two compounds ͻ͵ 
with antiviral activity: the nucleoside analogue cidofovir, and the TLR7 agonist ͻͶ 
imiquimod, are topical therapies that have been investigated with this aim. In small ͻͷ 
studies, cidofovir demonstrated response rates ranging from 40%-79% (8,9) and ͻ͸ 
imiquimod from 26%-100% (10). Recently, the CRUK-funded RT3 VIN clinical trial ͻ͹ 
randomised patients with VIN 3 to treatment with either cidofovir or imiquimod (11). ͻͺ 
Histologically confirmed, complete response rates were seen in 41/72 (57%) cidofovir ͻͻ 
patients and 42/69 (61%) imiquimod patients. A predictive biomarker that could ͳͲͲ 
identify patients likely to respond to specific treatments would facilitate optimal ͳͲͳ 
management of these patients. The RT3 VIN study provided valuable bio-resources to ͳͲʹ 
investigate potential biomarkers for response to topical therapy. ͳͲ͵ 
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The limited research available indicates that not all patients with VIN respond to ͳͲͶ 
treatment with cidofovir (9,11). In vitro studies have demonstrated that cidofovir ͳͲͷ 
causes selective inhibition of proliferation in HPV infected cells compared with HPV ͳͲ͸ 
negative cell lines (12,13), and also that cidofovir is more effective in cells containing ͳͲ͹ 
specifically a high-risk HPV infection (14). However, consideration of the data on ͳͲͺ 
HPV prevalence in VIN and response to cidofovir suggest that only a subset of HPV-ͳͲͻ 
positive VIN responds to cidofovir.  ͳͳͲ 
It is plausible therefore that a more refined knowledge of HPV status and biology, ͳͳͳ 
prior to treatment with cidofovir, is required to identify the patients most likely to ͳͳʹ 
respond. ͳͳ͵ 
Imiquimod is a non-nucleoside heterocyclic amine, which acts as an immune-ͳͳͶ 
response modifier. It induces activity of interferon α (IFNα), tumour necrosis factor α ͳͳͷ 
(TNFα) and interleukin-6 via stimulation of TLR7 (15). The mechanism of action of ͳͳ͸ 
imiquimod is hence linked to the direct stimulation of the innate immune system and ͳͳ͹ 
requires a host response to HPV infection in the first instance. HPV infection is likely ͳͳͺ 
to be most immunogenic in the context of a productive infection, when new viral ͳͳͻ 
particles are produced. Previous literature suggests that productive infections may be ͳʹͲ 
associated with low levels of methylation of viral DNA (16). This is consistent with ͳʹͳ 
high levels of HPV DNA methylation being associated with more advanced disease ͳʹʹ 
(17,18). It was therefore hypothesised that levels of HPV DNA methylation in VIN ͳʹ͵ 
might correlate with response to topical therapy with imiquimod. ͳʹͶ 
The primary objective of this study was to quantify HPV DNA methylation in VIN, ͳʹͷ 
and assess the association with response to topical treatment in the RT3 VIN clinical ͳʹ͸ 
trial cohort. The ultimate aim was to determine whether quantification of viral DNA ͳʹ͹ 
methylation had potential as a predictive biomarker to identify patients likely to ͳʹͺ 
benefit from topical therapy for VIN.  ͳʹͻ 
  ͳ͵Ͳ 
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Methods ͳ͵ͳ 
Patients and samples ͳ͵ʹ 
The study utilised bio-resources and clinical data from the RT3VIN clinical trial, the ͳ͵͵ 
design and eligibility criteria of this trial have been reported previously (11). Briefly, ͳ͵Ͷ 
180 women with histologically confirmed VIN 3 were randomised to receive topically ͳ͵ͷ 
administered cidofovir or imiquimod for 24 weeks. The primary endpoint was ͳ͵͸ 
histologically confirmed complete response in baseline lesions 6 weeks after ͳ͵͹ 
completion of treatment. Response to treatment with either cidofovir or imiquimod ͳ͵ͺ 
was determined by the absence of VIN in a tissue biopsy taken from the previously ͳ͵ͻ 
affected area 6 weeks following the completion of treatment. The presence of VIN 1 ͳͶͲ 
or greater was considered persistent disease indicating failure to respond. ͳͶͳ 
HPV testing was carried out on punch biopsies (4mm) available at baseline from the ͳͶʹ 
site of disease in 167 patients (93%,). Biopsies were stored in ThinPrep media ͳͶ͵ 
(Hologic, Marlborough, MA, USA) prior to processing. DNA was extracted using the ͳͶͶ 
Qiagen DNA mini kit (Qiagen, Hilden, Germany).  ͳͶͷ 
HPV detection ͳͶ͸ 
A type-specific PCR targeting the HPV 16 E6 region (19) was used to detect cases of ͳͶ͹ 
HPV 16. The Greiner PapilloCheck HPV genotyping assay (Greiner Bio-One, ͳͶͺ 
Frickenhausen, Germany), which tests for 24 HPV genotypes (HPV 6, 11, 40, 42, 43, ͳͶͻ 
44, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82), was used ͳͷͲ 
as per manufacturers instructions to test for the presence of non-HPV 16 genotypes. ͳͷͳ 
HPV DNA methylation was only investigated in cases that tested positive for HPV 16 ͳͷʹ 
(defined as testing HPV 16 positive using HPV 16 E6 PCR and/or PapilloCheck). ͳͷ͵ 
HPV DNA methylation ͳͷͶ 
DNA methylation was quantified in the HPV promotor, E2 and L1/L2 regions. These ͳͷͷ 
regions were assessed due to the possible functional significance of methylation in ͳͷ͸ 
regulating E6 and E7 oncogene expression (promotor and E2 region) and their ͳͷ͹ 
established association with cervical neoplasia (L1/L2) (17,18). Positioning of primer ͳͷͺ 
sequences reflected sequence constraints and the desire to amplify the maximum ͳͷͻ 
number of CpG sites within a single reaction. Viral targets were assessed rather than ͳ͸Ͳ 
cellular ones, because the putative mechanisms of action of cidofovir and imiquimod ͳ͸ͳ 
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imply specificity to virus-infected cells. DNA (500 ng) was sodium bisulfite treated ͳ͸ʹ 
using the EZ-DNA methylation kit (Zymo Research Corp, CA, USA). DNA ͳ͸͵ 
methylation was assessed by pyrosequencing of the E2 ORF, L1/L2 overlap, and ͳ͸Ͷ 
promoter regions using a Qiagen PyroMark Q96 ID system as previously described ͳ͸ͷ 
(20). Each assay targeted multiple CpGs and all assays were performed in duplicate. ͳ͸͸ 
Methylation levels are reported as means for each region. These assays were specific ͳ͸͹ 
for HPV 16 only. Stringent quality assurance checks were applied to the methylation ͳ͸ͺ 
data, including assessment of bisulphite conversion and primer extension; additional ͳ͸ͻ 
quality control assessments were performed by the pyrosequencing software, and any ͳ͹Ͳ 
sample classed a ‘fail’ was excluded from the analysis. All samples were run in ͳ͹ͳ 
duplicate and the standard deviation was calculated for each CpG site analysed. This ͳ͹ʹ 
data was used to demonstrate the intra-run reproducibility of the assay and provided ͳ͹͵ 
an additional quality control step; samples were excluded from further analysis if a ͳ͹Ͷ 
value was beyond 3 standard deviations of the mean standard deviation calculated for ͳ͹ͷ 
all CpG sites for each region. This final step was performed to enhance the quality of ͳ͹͸ 
the data set by excluding any samples generating dissimilar duplicate readings. ͳ͹͹ 
 ͳ͹ͺ 
Biomarker development and statistics ͳ͹ͻ 
Guidelines for predictive biomarker development were adhered to ͳͺͲ 
(http://wwwcancerresearchukorg/sites/default/files/prognostic_and_predictivepdfȌ,  ͳͺͳ ȋ21). A statistical analysis plan was developed a priori and the laboratory team were ͳͺʹ 
blinded to clinical outcomes. The distribution of HPV DNA methylation level in the ͳͺ͵ 
RT3 VIN baseline cohort was first established (biomarker discovery –stage 1). ͳͺͶ 
Retrospective correlation with response to treatment of patients in the RT3 VIN ͳͺͷ 
clinical trial was then assessed (biomarker discovery – stage 2). Mann-Whitney U ͳͺ͸ 
tests were used to identify statistically significant differences between methylation ͳͺ͹ 
levels in responders and non-responders. A Bonferroni correction to account for ͳͺͺ 
multiple comparisons was incorporated making a p value of p = 0.016 significant. ͳͺͻ 
Significant findings for any biomarker in either treatment cohort were further ͳͻͲ 
investigated in both cohorts using ROC curve analysis to find optimum cut offs for ͳͻͳ 
sensitivity and specificity. ͳͻʹ 
Results ͳͻ͵ 
Research. 
on June 12, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 9, 2017; DOI: 10.1158/1078-0432.CCR-17-0040 
ͺ  
Variability in HPV DNA methylation ͳͻͶ 
One-hundred-and-thirty-six cases (136/167) tested positive for HPV 16 DNA (Figure ͳͻͷ 
1). The proportion of cases yielding analysable data in HPV DNA methylation assays ͳͻ͸ 
varied depending on the region examined (E2 = 82, L1/L2 = 93 and promoter = 122). ͳͻ͹ 
The higher rates of inadequate data in the E2 and L1/L2 regions most likely reflect ͳͻͺ 
disruption of these regions associated with viral integration. The degree of ͳͻͻ 
methylation of HPV DNA varied between the regions (Figure 2). A bimodal ʹͲͲ 
distribution of values was observed for the E2 and L1/L2 regions, contrasting with ʹͲͳ 
more uniformly low levels of methylation in the promoter region.  ʹͲʹ 
HPV DNA methylation and response to treatment ʹͲ͵ 
Correlation between methylation levels and response to treatment was retrospectively ʹͲͶ 
assessed (Figure 3). Of the 136 cases that tested positive for HPV 16, twenty-nine ʹͲͷ 
cases did not have post-treatment clinical outcome data; therefore 107 cases were ʹͲ͸ 
available for analysis.  ʹͲ͹ 
For the E2 region 63/107 cases gave analysable data; for the L1/L2 region 73/107 ʹͲͺ 
cases; and for the promoter region 95/107 cases. A flow chart depicting how the final ʹͲͻ 
numbers of patients suitable for analysis were derived is shown in Figure 1. Levels of ʹͳͲ 
E2, L1/L2 and promoter region methylation were then compared between patients ʹͳͳ 
who responded to treatment, and those who did not.  ʹͳʹ 
E2 Methylation ʹͳ͵ 
For patients treated with cidofovir with clinical outcome data (n=54), the E2 ʹͳͶ 
methylation assay generated a result in 30/54 (55.6%) of cases; 17/30 (56.7%) ʹͳͷ 
responded to treatment and 13/30 (43.3%) did not. Median E2 methylation was ʹͳ͸ 
significantly higher in patients who responded (9.14%, inter-quartile range (IQR) = ʹͳ͹ 
4.28% - 82.03%) to cidofovir than in patients who did not (1.85%, IQR = 1.01% - ʹͳͺ 
3.26%), (U = 18.00, p = <0.0001) (Figure 1.3).  ʹͳͻ 
For patients treated with imiquimod with clinical outcome data (n=53), the E2 ʹʹͲ 
methylation assay generated a result in 33/53 (62.3%) of cases; 17/33 (51.5%) ʹʹͳ 
responded and 16/33 (48.5%) did not. Median E2 methylation was lower (2.57%, IQR ʹʹʹ 
= 2.21% - 4.20%) in patients who responded to treatment than in patients who did not ʹʹ͵ 
(24.22%, IQR 3.15% - 87.94%), although this finding did not reach the required ʹʹͶ 
statistical significance (U = 196.00, p = 0.03).  ʹʹͷ 
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L1/L2 Methylation ʹʹ͸ 
For cidofovir treated patients with clinical outcome data (n=54), the L1L2 ʹʹ͹ 
methylation assay generated a result in 39/54 (72.2%) of cases; 17/39 (43.6%) ʹʹͺ 
responded to treatment and 22/39 (56.4%) did not. Median L1/L2 methylation was ʹʹͻ 
found to be non-significantly higher (59.03%, IQR = 11.17% - 86.15%) in patients ʹ͵Ͳ 
who responded to cidofovir than patients who did not respond (9.62%, IQR = 5.25% - ʹ͵ͳ 
28.41%), (U = 113.00, p = 0.04).  ʹ͵ʹ 
For patients treated with imiquimod with clinical outcome data (n=53), the L1/L2 ʹ͵͵ 
assay generated a result in 34/53 (64.2%) of cases; 19/34 (55.9%) responded to ʹ͵Ͷ 
treatment and 15/34 (44.1%) did not. Median L1/L2 methylation was non-ʹ͵ͷ 
significantly lower in patients who responded to imiquimod (11.72% IQR = 6.81% - ʹ͵͸ 
62.13%) than in those patients who did not (37.60%, IQR = 12.49% - 77.69%), (U = ʹ͵͹ 
181.00, p = 0.34). ʹ͵ͺ 
Promoter Methylation ʹ͵ͻ 
For cidofovir treated patients with clinical outcome data (n=54), the promoter ʹͶͲ 
methylation assay generated a result in 51/54 (94.4%) cases; 26/51 (51.0%) responded ʹͶͳ 
to treatment and 25/51 (49.0%) did not. Median promoter methylation was similar ʹͶʹ 
between patients who responded to cidofovir (0.20%, IQR = 0.04% - 0.73%) and ʹͶ͵ 
patients who did not (0.24%, IQR = 0.00% - 0.55%), (U = 295.5, p = 0.57).  ʹͶͶ 
For patients treated with imiquimod with clinical outcome data (n=53), the promoter ʹͶͷ 
methylation assay generated a result in 44/53 (83.0%). A complete response to ʹͶ͸ 
treatment was seen in 24/44 (54.5%) and 20/44 (45.5%) did not respond completely. ʹͶ͹ 
Median promoter methylation was non-significantly lower (0.16%, IQR = 0.00% - ʹͶͺ 
0.44%) in patients who responded to imiquimod than in those patients who did not ʹͶͻ 
(0.26%, IQR = 0.10% - 1.07%) (U = 292.5, p = 0.21).  ʹͷͲ 
Sensitivity and specificity of E2 methylation  ʹͷͳ 
ROC curve analysis was performed to investigate the ability of methylation of the E2 ʹͷʹ 
region to discriminate between patients who responded to treatment and those who ʹͷ͵ 
did not (figure 4). Quantification of E2 methylation was able to discriminate between ʹͷͶ 
responders and non-responders, with an AUC of 0.919 (95% CI 0.822-1.000). ʹͷͷ 
Quantification of E2 methylation also demonstrated the ability to distinguish ʹͷ͸ 
imiquimod responders from non-responders, with an AUC of 0.721 (95% CI = 0.538-ʹͷ͹ 
0.903).  ʹͷͺ 
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Table 1 shows the sensitivity and specificity achievable at various cut-off levels of ʹͷͻ 
methylation. This demonstrated that high sensitivity and specificity (88.2 and 84.6%) ʹ͸Ͳ 
to identify potential responders to treatment with cidofovir, could be achieved using a ʹ͸ͳ 
cut-off value of 4% methylation. For imiquimod, a cut-off of 4% E2 methylation ʹ͸ʹ 
showed sensitivity and specificity of 70.6 and 62.5%. Use of a higher cut-off of 10% ʹ͸͵ 
would make the assay more sensitive but substantially less specific.   ʹ͸Ͷ 
In the population treated with cidofivir, in both univariable and multivariable ʹ͸ͷ 
(including the randomisation stratification factors of unifocal or multifocal disease, ʹ͸͸ 
and first presentation or recurrent disease) logistic regression models there was strong ʹ͸͹ 
evidence that the odds of response were significantly higher in patients with ≥4% E2 ʹ͸ͺ 
methylation compared to those with <4% E2 methylation  (n=30; univariable odds ʹ͸ͻ 
ratio: 25.67, 95% CI: 3.63-181.44, p=0.001; multivariable odds ratio: 52.51, 95% CI: ʹ͹Ͳ 
3.88-709.90, p=0.003). In the population treated with imiquimod, there was weaker ʹ͹ͳ 
evidence that the odds of response were lower in patients with ≥4% E2 methylation ʹ͹ʹ 
compared to those with <4% E2 methylation  (n=33; univariable odds ratio: 0.25, ʹ͹͵ 
95% CI: 0.06-1.07, p=0.062; multivariable odds ratio: 0.27, 95% CI: 0.06-1.19, ʹ͹Ͷ 
p=0.083). ʹ͹ͷ 
Cases without E2 methylation data ʹ͹͸ 
Further analysis was undertaken of those cases for which E2 methylation data was not ʹ͹͹ 
obtained. E2 methylation data was not obtained for 85/167 (50.9%) of the research ʹ͹ͺ 
samples from the RT3 VIN trial, of which seventy-two had clinical outcome data. ʹ͹ͻ 
Thirty-eight cases were treated with cidofovir and 34 cases were treated with ʹͺͲ 
imiquimod. Of the 38 cases treated with cidofovir, 19/38 (50.0%) responded to ʹͺͳ 
treatment and 19/38 (50.0%) failed to respond to treatment. Of the 34 cases treated ʹͺʹ 
with imiquimod, 21/34 (61.8%) and 13/34 (38.2%) failed to respond. ʹͺ͵ 
The cases without E2 methylation were separated into cases in which there was no ʹͺͶ 
detectable HPV 16 DNA and cases that failed the HPV 16 assay quality controls. Of ʹͺͷ 
the HPV 16 negative cases (n=31), 28 had clinical outcome data and two approaches ʹͺ͸ 
were taken in their analysis. Firstly, there were 14 patients treated with cidofovir of ʹͺ͹ 
which, more patients responded 9/14 (64.3%) to treatment than did not 5/14 (35.7%). ʹͺͺ 
Similarly, there were 14 patients treated with imiquimod and again, these patients ʹͺͻ 
were more likely to respond to treatment than not (10/14 (71.4%) vs. 4/14 (28.6%)). ʹͻͲ 
The second approach was to consider cases displaying complete absence of HPV ʹͻͳ 
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DNA, in comparison with those in which an HPV type other than HPV 16 was ʹͻʹ 
detected. Of the 28 cases, 14 had no HPV DNA detected and 14 had a non-HPV 16 ʹͻ͵ 
genotype detected. In cases with no detectable HPV DNA, 12/14 (85.7%) responded ʹͻͶ 
to treatment (six in the cidofovir arm and six in the imiquimod arm) and 2/14 (14.3%) ʹͻͷ 
failed to respond (one in each treatment arm). In cases where an HPV type other than ʹͻ͸ 
HPV 16 was detected, 7/14 (50.0%) responded to treatment (three in the cidofovir are ʹͻ͹ 
and four in the imiquimod arm) and 7/14 (50.0%) failed to respond to treatment (four ʹͻͺ 
in the cidofovir arm and three in the imiquimod arm).  ʹͻͻ 
HPV 33 was the second most common genotype, detected in 8 (non-HPV 16) ͵ͲͲ 
samples. Of these cases, 7/8 had clinical data (five cases were treated with cidofovir ͵Ͳͳ 
and two cases with imiquimod). For the cidofovir cases, 3/5 failed to respond to ͵Ͳʹ 
treatment and 2/5 responded. For the imiquimod case, one case responded and one ͵Ͳ͵ 
case failed to respond.  ͵ͲͶ 
The remaining 54/85 (63.5%) cases without E2 DNA methylation data were excluded ͵Ͳͷ 
as they did not meet assay quality controls standards; 44 of these cases had clinical ͵Ͳ͸ 
outcome data. Twenty-four cases were treated with cidofovir, and 10/24 (41.7%) ͵Ͳ͹ 
responded to treatment while 14/24 (58.3%) failed to respond. Twenty cases were ͵Ͳͺ 
treated with imiquimod, of which 11/20 (55.0%) responded to treatment and 9/20 ͵Ͳͻ 
(45.0%) failed to respond. ͵ͳͲ 
Discussion ͵ͳͳ 
The principle finding of this work was that DNA methylation of the HPV E2 gene, ͵ͳʹ 
assessed in pre-treatment biopsies from patients with VIN 3, significantly correlated ͵ͳ͵ 
with response to treatment with cidofovir. There was weaker evidence (not significant ͵ͳͶ 
after Bonferroni correction) of an association between E2 DNA methylation and ͵ͳͷ 
response to treatment with imiquimod. High levels of methylation were highly ͵ͳ͸ 
predictive of a clinical response to cidofovir, and conversely, low levels of ͵ͳ͹ 
methylation were associated with a clinical response to treatment with imiquimod.  ͵ͳͺ 
Several previous studies have demonstrated a strong association between L1/L2 ͵ͳͻ 
methylation and cervical neoplasia (17,18). Increased methylation of the E2 and ͵ʹͲ 
L1/L2 regions is also observed in cervical cancers (20). It was notable that in the ͵ʹͳ 
current study, while L1/L2 methylation showed some correlation with treatment ͵ʹʹ 
response, a stronger correlation was observed between response and methylation of ͵ʹ͵ 
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the E2 region (median E2 methylation was 9.14% in patients who responded to ͵ʹͶ 
treatment with cidofovir and 2.85% in patients who did not respond).  ͵ʹͷ 
It has been proposed that in cervical HPV infections, increased methylation of the ͵ʹ͸ 
L1/L2 region may indicate the duration of an infection. It has also been shown that ͵ʹ͹ 
increased methylation correlates with integration of the virus into the host genome ͵ʹͺ 
(22). It is not clear why E2 methylation should correlate with response to treatment ͵ʹͻ 
with cidofovir. It is unclear if it is the level of methylation per se that is important or ͵͵Ͳ 
if methylation is a surrogate marker of another relevant process. This is partly due to ͵͵ͳ 
the exact mechanism of action of cidofovir in HPV infected cells being poorly ͵͵ʹ 
defined. It is possible that the action of cidofovir in this context is as a de-methylating ͵͵͵ 
agent. This is a somewhat speculative suggestion but is consistent with cidofovir ͵͵Ͷ 
being a nucleoside analogue with similar structure to the established demethylating ͵͵ͷ 
agent decitabine (used in treatment of myelodysplatic blood conditions (23)). This ͵͵͸ 
possibility is further supported by a study of cases of failed cidofovir treatment in ͵͵͹ 
recurrent respiratory papillomatosis (caused by HPV 11), which correlated treatment ͵͵ͺ 
failure with uniformly low levels of methylation (24). Alternatively E2 methylation ͵͵ͻ 
maybe a surrogate marker of another relevant process, e.g. it may be associated with ͵ͶͲ 
more advanced infections with lower levels of p53 protein. This would be consistent ͵Ͷͳ 
with the suggestion that that the selectivity of cidofovir for transformed cells is due to ͵Ͷʹ 
the absence, or perturbation, of normal DNA repair pathways associated with ͵Ͷ͵ 
dysfunctional p53 mediated signalling (25). Cidofovir has been shown to generate ͵ͶͶ 
double-stranded breaks in cellular DNA, which can be repaired in normal cells, but ͵Ͷͷ 
not in tumour cells (26). In HPV infected cells the level of p53 is reduced through ͵Ͷ͸ 
ubiquitination and proteosomal degradation mediated by the HPV E6 oncoprotein, ͵Ͷ͹ 
expression of which can become deregulated as a result of HPV integration and/or ͵Ͷͺ 
HPV DNA methylation (16). HPV integration and increased methylation could ͵Ͷͻ 
therefore be more common in cells that have lower levels of p53/pRb, and may be ͵ͷͲ 
more likely to respond to cidofovir. The strong correlation between increased E2 ͵ͷͳ 
methylation and response to treatment could therefore be because E2 methylation is a ͵ͷʹ 
surrogate marker of absent/low level p53/pRb.  ͵ͷ͵ 
Contrary to the case with cidofovir, mean E2 methylation was lower in patients who ͵ͷͶ 
responded to imiquimod (11.6% vs. 40.0%), although this finding was not statistically ͵ͷͷ 
significant. Imiquimod acts as an immunomodulator by activating TLR7, which in ͵ͷ͸ 
turn, enhances the innate immune system by stimulating the synthesis of pro-͵ͷ͹ 
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inflammatory cytokines, especially IFNα, which enhance cell-mediated cytoloytic ͵ͷͺ 
activity against viral targets (15,27,28). However, the enhanced host immune ͵ͷͻ 
response needs direction in order to be effective and it is plausible that a proliferative ͵͸Ͳ 
HPV infection provides this direction. ͵͸ͳ 
The success of HPV is often attributed to its ability to hide from normal host defence ͵͸ʹ 
mechanisms permitting persistent infection (16). Persistent infection can be associated ͵͸͵ 
with development of high-grade intraepithelial neoplasia, in which HPV integration ͵͸Ͷ 
and increased HPV DNA methylation are common (17,18,29). Similarly, low levels ͵͸ͷ 
of HPV DNA methylation strongly correlate with the presence of episomal HPV (30). ͵͸͸ 
Hence HPV DNA methylation may be higher in infections that successfully evade ͵͸͹ 
host immunity. Conversely, cases of early, episomal HPV infections with lower levels ͵͸ͺ 
of HPV DNA methylation, are more likely to stimulate an immune response that can ͵͸ͻ 
then be enhanced by the action of imiquimod. The values obtained for HPV DNA ͵͹Ͳ 
methylation of the E2 and L1/L2 regions showed a bimodal distribution. Reports in ͵͹ͳ the literature exist correlating higher levels of E2 and Lͳ/Lʹ methylation with high-͵͹ʹ grade cervical and vulval disease ȋʹͲ,͵ͳ-͵ͷȌ.  Based on this, it is perhaps surprising that ͵͹͵ we observed consistently high levels of methylation in (PV ͳ͸ positive cases in this ͵͹Ͷ cohort of V)N ͵. )t is possible that these higher levels of methylation reflect the ͵͹ͷ influences of a small number of other influences such as viral integration.  ͵͹͸ 
This is the first study investigating the potential role of viral methylation as a ͵͹͹ 
predictive biomarker in the treatment of VIN. HPV E2 DNA methylation meets the ͵͹ͺ 
criteria required for early predictive biomarker assay discovery and development. E2 ͵͹ͻ 
methylation varied in the RT3 VIN cohort, which is highly representative of the ͵ͺͲ 
cohort to which the biomarker would apply. Strong correlations between high E2 ͵ͺͳ 
methylation and response to treatment with cidofovir and low E2 methylation and ͵ͺʹ 
response to treatment with imiquimod were identified retrospectively. However, prior ͵ͺ͵ 
to further qualification in the context of a clinical trial utilising E2 methylation as a ͵ͺͶ 
biomarker in the randomisation process, its ‘fitness for purpose’ needs to be ͵ͺͷ 
addressed. These criteria may include cost efficiency, ease of incorporation into the ͵ͺ͸ 
clinical setting, efficiency of the assay testing the biomarker and patient coverage. ͵ͺ͹ 
Incorporating the assay into the clinical setting is feasible. Testing could be carried ͵ͺͺ 
out on remaining biopsy material following histological assessment (the assay has ͵ͺͻ 
previously been successfully applied to DNA from fixed pathology blocks (22)). ͵ͻͲ 
Assessment of methylation state using bisulphite conversion and pyrosequencing is a ͵ͻͳ 
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relatively standard assay and this equipment is likely to be widely available if HPV ͵ͻʹ 
DNA methylation is adopted as a triage assay in a cervical screening workflow (36).  ͵ͻ͵ 
The bio-resources used were obtained within a randomised clinical trial and were ͵ͻͶ 
associated with robust clinical endpoints (11). The material was rigorously quality ͵ͻͷ 
assured and controlled. Viral characteristics were assessed using well-validated ͵ͻ͸ 
assays, with stringent quality assurance and control. ͵ͻ͹ 
A significant concern was the 85/167 (50.9%) patients for whom an E2 methylation ͵ͻͺ 
result was not available, potentially hindering the clinical application of the test. It ͵ͻͻ 
was also a concern that these cases could potentially represent a specific subset of ͶͲͲ 
patients, and their exclusion might introduce bias into the findings. However, the ͶͲͳ 
overall response rates for patients with no E2 data were similar to the response rates ͶͲʹ 
seen in the main clinical trial, which suggests that the risk of bias appears minimal. ͶͲ͵ 
The majority of excluded cases, were associated with failure to meet stringent assay ͶͲͶ 
quality controls (n=54); this was most likely attributable to insufficient DNA in the ͶͲͷ 
sample used for bisulphite conversion, or poor DNA quality. The methylation assay ͶͲ͸ 
requires a specific DNA concentration in the input sample, but the relative ͶͲ͹ 
concentration of human vs. viral DNA was not determined. The assay failures ͶͲͺ 
associated with insufficient DNA appear likely to be attributable to relatively low ͶͲͻ 
concentrations of viral DNA. In order to improve coverage in future studies, efforts ͶͳͲ 
would need to be made to improve the quality and quantity of DNA through Ͷͳͳ 
optimisation of sample collection, processing and storage. Ͷͳʹ 
The remaining (n=31) for which E2 data was unavailable did not have detectable Ͷͳ͵ 
HPV 16 DNA in the sample. In the presence of HPV DNA of another genotype, ͶͳͶ 
response rates were 50.0% in each treatment arm, however a clinical response was Ͷͳͷ 
seem more frequently in cases with no detectable HPV DNA (85.7%). The number of Ͷͳ͸ 
cases is too small to draw any significant conclusions from this, however it raises the Ͷͳ͹ 
possibility that management of HPV negative patients should be perhaps considered Ͷͳͺ 
separately. The data suggest that topical therapy may still be highly effective in this Ͷͳͻ 
group of patients. HPV 33 was the second most common detected HPV genotype. In ͶʹͲ 
order to improve coverage of the assay, it may be of benefit to develop the E2 Ͷʹͳ 
methylation assay for this genotype. Although it is important to note that an HPV 33 Ͷʹʹ 
assay might not confer the same predictive value as observed with HPV 16.  Ͷʹ͵ 
Research. 
on June 12, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 9, 2017; DOI: 10.1158/1078-0432.CCR-17-0040 
ͳͷ  
Potential biomarkers were investigated in all patients enrolled in the trial for whom ͶʹͶ 
pre and post treatment biopsies were available, even if they did not adhere to the Ͷʹͷ 
treatment regime. In the cidofovir arm, 78/89 patients adhered to the treatment Ͷʹ͸ 
regime; in the imiquimod arm, 78/91 patients adhered. Patients who did not adhere to Ͷʹ͹ 
the treatment regime, typically reduced dosing due to side-effects. Inclusion of all Ͷʹͺ 
patients allowed more accurate estimation of real-world clinical utility but may mean Ͷʹͻ 
that the performance of the biomarkers in the optimum setting may have been Ͷ͵Ͳ 
underestimated. Ͷ͵ͳ 
The findings of this research indicate that imiquimod and cidofovir may be effective Ͷ͵ʹ 
in two biologically distinct groups. This observation invites a re-evaluation of how Ͷ͵͵ 
topical treatment for VIN is conceived and delivered. To ensure that individual Ͷ͵Ͷ 
patients receive an effective therapy, treatment could be personalised through use of a Ͷ͵ͷ 
biomarker. Further development of E2 methylation as a predictive biomarker in the Ͷ͵͸ 
treatment of VIN with cidofovir and imiquimod should be considered. This would Ͷ͵͹ 
require validation in an independent cohort, and efforts would need to be made to Ͷ͵ͺ 
further optimise the E2 methylation assay to reduce the number of failed results; Ͷ͵ͻ 
additionally, a pragmatic approach would be required to manage women with invalid ͶͶͲ 
data.  ͶͶͳ 
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 ͷͺ͹ 
 ͷͺͺ 
Figure Legends: ͷͺͻ 
Figure 1. Flow chart indicating how final numbers of patients suitable for ͷͻͲ 
analysis were derived. ͷͻͳ 
Figure 2.Variation of regional HPV methylation in the RT3 VIN cohort. The ͷͻʹ 
median value was calculated for each region from all CpG sites tested and is ͷͻ͵ 
represented by a horizontal bar. Six CpG sites were tested for the E2 region (nt 3411, ͷͻͶ 
nt 3414, nt 3416, nt 3432, nt 3435, nt 3447), four CpG sites were tested for the L1/L2 ͷͻͷ 
region (nt 5615, nt 5606, nt5609, nt 5600) and five CpG sites were tested for the ͷͻ͸ 
promoter region (nt 31, nt 37, nt 43, nt 52, nt 58). Bars represent inter-quartile range. ͷͻ͹ 
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Figure 3. HPV DNA methylation in treatment responders and non-responders. ͷͻͺ 
Upper panel shows E2 region methylation, middle panel L1/L2 region, and lower ͷͻͻ 
panel promotor region. Any treatment represents combined data from both cidofovir ͸ͲͲ 
and imiquimod treatment arms. Boxes represent the interquartile range, the central bar ͸Ͳͳ 
represents the median value, and whiskers represent minimum and maximum values. ͸Ͳʹ 
Figure 4. ROC curve analysis. The upper panel demonstrates the ability of E2 ͸Ͳ͵ 
methylation levels to distinguish cidofovir responders from non-responders. N = 30. ͸ͲͶ 
Increasing level of E2 methylation demonstrates ‘excellent’ ability to distinguish ͸Ͳͷ 
cidofovir responders from non-responders with AUC 0.919 (95%CI 0.882–1.00). The ͸Ͳ͸ 
lower panel demonstrates the ability of E2 methylation to distinguish imiquimod ͸Ͳ͹ 
responders from non-responders. N = 33. Decreasing E2 methylation demonstrated ͸Ͳͺ 
‘fair to good’ ability to distinguish imiquimod responders from non-responders with ͸Ͳͻ 
an AUC of 0.721 (95%CI 0.538–0.903). ͸ͳͲ 
Table 1. The level of methylation in the first column is based on the average ͸ͳͳ 
methylation found from the multiple CpG’s tested in the E2 region. The smallest cut-͸ͳʹ 
off value represents the minimum E2 methylation value obtained -1 and the largest ͸ͳ͵ 
cut off point represents the maximum value +1. Cut-off values between these are the ͸ͳͶ 
average of two consecutive ordered observed test values, generated by SPSS ROC ͸ͳͷ 
analysis.  ͸ͳ͸ 
 ͸ͳ͹ 
 ͸ͳͺ 
 ͸ͳͻ 
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180 cases recruited into RT3 VIN trial 
30 patients with 
analysable E2 
methylation data 
34 cases with 
analysable L1/L2 
methylation data 
167 cases with available research 
biopsy 
136 cases testing positive for the 
presence of HPV 16 DNA 
54 cases with clinical outcome data 
(3 = lost to follow up, 10 = withdrew prior 
to biopsy and one had an invalid biopsy) 
39 cases with 
analysable L1/L2 
methylation data 
44 cases with 
analysable promoter 
methylation data 
68 cases in imiquimod arm 68 cases in cidofovir arm 
53 cases with clinical outcome data  
(4 = lost to follow up, 11 = withdrew prior 
to biopsy) 
33 cases with 
analysable E2 
methylation data 
51 cases with 
analysable promoter 
methylation data 
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Table 1. Sensitivity and specificity of different E2 methylation cut-off levels to distinguish responders and non-
responders.  
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